Boston Therapeutics $BTHE Announces Strategic Marketing Agreement for SUGARDOWN®

Posted by Samy Goldfarb

May 20, 2014 at 12:05 PM

http://www.sugardown.com/

Boston Therapeutics (BTHE-OTC), a developer of compounds that address blood sugar management and inflammatory disease, has announced the signing of a strategic marketing agreement with Benchworks SD, LLC, a branding and marketing agency, aimed at increasing brand awareness and sales of SUGARDOWN®.
 
SUGARDOWN is Boston Therapeutics’ currently marketed dietary supplement that, when taken prior to meals, supports a reduction in the post-meal elevation in glucose resulting in healthy blood sugar levels. Clinical studies conducted at the University of Sydney in Australia indicated that the consumption of SUGARDOWN prior to a high carbohydrate meal of rice resulted in lower incremental area under the curve (iAUC) measurements for glucose and insulin, indicating a reduction in post-meal elevation of blood glucose and insulin when compared with the control group.
 
Benchworks plans to maximize brand recognition by positioning SUGARDOWN as an adjunct to diet and exercise, beyond the current intended use as a dietary supplement, to better manage blood sugar levels. Benchworks plans to take a three-pronged approach in order to broaden awareness of the potential benefits of SUGARDOWN and increase brand recognition: (1) increase awareness among people who may be at risk of developing diabetes and their caregivers; (2) create a bond with healthcare educators and nutritionists who would recommend SUGARDOWN for their patients; and (3) strengthen SUGARDOWN’s medical profile by continuing to build on new data from additional clinical trial results and new scientific findings. 

Read More

Topics: BTHE

Boston Therapeutics (BTHE-OTC) Inks Agreement with Patheon for BTI-320

Posted by Karen Goldfarb

May 6, 2014 at 10:35 AM

Boston Therapeutics, Inc., along with its Hong Kong-based strategic partner Advance Pharmaceutical Company, announced today the signing of agreement with pharmaceutical manufacturing company, Patheon Inc. This agreement is to manufacture pharmaceutical-grade tablets of BTI-320, the Company’s lead product candidate designed to reduce post-meal elevation of blood glucose.

This agreement was finalized in anticipation of Boston Therapeutics’ predicted IND filing in late 2014, as well as the Company’s planned international Phase III trial for BTI-320, which could initiate in 2015. One batch of BTI-320 is expected to be manufactured within a six-month timeframe, during which all methods development, analytical, stability, and other necessary tests will be performed under the IND requirements.

Read More

Topics: BTHE

CEO Jeffrey Kraws Live Interview on Pharma M&A Activity with ARISE News

Posted by Laura Swartz

May 1, 2014 at 12:29 PM

The segment below is an excerpt from ARISE TV's Arise XChange news program, aired live from 5 pm to 5:30 pm on Wednesday, April 30. Host Andrew Schmertz and Crystal Research CEO and Senior Pharmaceutical Analyst Jeffrey Kraws discuss recent M&A activity in the pharmaceutical industry, including Pfizer's proposed buyout of AstraZeneca.

Clip length: 5:34

Read More

Topics: Crystal Research Associates

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic